Abstract:A novel and simple liquid chromatographic (LC) method was developed for quantification of a new anticancer compound, chloride 3-methyl-9-(2-oxa-2λ5-2 H -1,3,2-oxazaphosphorine-2-cyclohexyl)-3,6,9-triazaspiro [5.5] undecane (SLXM-2) in rat plasma. The present method used protein precipitation for extraction of SLXM-2 from rat plasma. Separation was carried out on a reversed-phase C 18 column (150 mm × 4.6 mm i.d., 5 μm). The mobile phases consisted of acetonitrile and 2 mM sodium dodecyl sulfate (SDS) (24:76, v/v ). The flow rate was 1.0 mL min −1 . A diode-array detector (DAD) was used and the column effluent was monitored at 192 nm. Regression equations revealed good linear relationship between the peak area and the concentration. The correlation coefficient was 0.9996. The relative standard deviations (RSD) of the precision and accuracy were <9.0% (intra-day) and <6.1% (inter-day), respectively. The recovery and stability were found satisfactory during the study. The method was successfully applied for the pharmacokinetic study of SLXM-2 in rats. After a single dose (400 mg kg −1 ) of SLXM-2 was given to rats by intravenous injection, the half-life of SLXM-2 was 0.304 h, the area under the plasma concentration–time curve was 673.1 μg h mL −1 and the maximal plasma concentration was 1534.9 ± 185.8 μg mL −1 .

Determination of Chloride 3-Methyl-9-(2-oxa-2λ5-2 H -1,3,2-oxazaphosphorine-2-cyclohexyl)-3,6,9-triazaspiro [5.5] undecane (SLXM-2) in Rats by LC: Application to a Pharmacokinetic Study